Emergent BioSolutions / EBS

About Emergent BioSolutions

2273 Research Blvd., Suite 400, Rockville, Md. 20850
www.emergentbiosolutions.com | 301-795-1800 | Founded: 1998

Industry: Biotechnology | Category: Public Companies

Emergent BioSolutions went public in November, raising $52.4 million. Not long after, the federal government canceled a $877.5 million contract with VaxGen, which was supposed to have provided 75 million doses of a new-generation anthrax vaccine for the national stockpile.
The government has bought 10 million doses of Emergent's vaccine for the stockpile, but the cancellation of the VaxGen contract leaves a hole in the government's efforts against anthrax, one that Emergent would like to fill. The problem with Emergent's vaccine, however, is that it requires as many as six doses; the government wants fewer. So Emergent is testing a new version of the vaccine that uses an adjuvant, or additive, to help enhance the vaccine and speed its ability to boost immune response in the body.

2006 Financial Data

Revenues: $152,732,000 | Net Income: $22,793,000
Asssets: $238,255,000 | Earnings Per Share: $0.93
Total employees: 470 | Local employees: 150